97 results on '"Yoshimura, Tomoaki"'
Search Results
2. Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?
3. Comment on: Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug–drug interactions
4. Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database
5. Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System
6. Comment on: Drugs That Interact With Colchicine via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)
7. Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions
8. Evaluation of the therapeutic effects and tolerability of modified lenvatinib administration methods for unresectable hepatocellular carcinoma: A preliminary study
9. Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma
10. Analysis of pharmacological interventions among hospitalised patients with COVID‑19: A focus on severe cases
11. Effects of Pharmacist-Led Dementia Care Round Interventions on the Use of Sleep Medications
12. Impact of continuous pharmacist intervention for injectable antimicrobials on the treatment of patients with Escherichia coli bacteremia
13. Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database
14. Elucidation of optimal proteinuria management based on the risk of ramucirumab‑induced proteinuria
15. Management of the Clinical Pathway Based on the Guidelines and Construction of a Monitoring System for the Optimization of Antimicrobial Prophylaxis in Surgery
16. Sleep-Prolonging Effect of Memantine for Short Periods and Low Doses
17. Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
18. Influences of dispersion media for chemically modified cellulose nanofibers on rheological and mechanical properties of cellulose nanofiber reinforced high-density polyethylene
19. Evaluation of the Utility of the Original Nutrition Table for the Patients Undergoing Monotherapy with Oral Anticancer Agents
20. Retrospective Observational Study on Predictors of Body Weight and BNP Teduction in Cases of Tolvaptan Induction for Heart Failure
21. Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
22. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab
23. Evaluation of Antimicrobial Stewardship Team Intervention and Compliance Rate of Guidelines for Antimicrobial Prophylaxis in Surgery: A Multicenter Study in Gifu Prefecture
24. Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
25. A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma
26. Evaluation of an Intervention for Patients Using Aminoglycosides Based on the Antimicrobial TDM 2016 Guideline by Pharmacists
27. Relationship between PONV and S-1 Adjuvant Chemotherapy-associated Nausea
28. Association between Severe Neutropenia Induced by Ramucirumab Plus Paclitaxel Combination Therapy and Overall Survival in Advanced Gastric Cancer
29. Single-centre retrospective observational study comparing trough blood concentration and safety of teicoplanin formulations
30. Multi-functional effect of alkenyl-succinic-anhydride-modified microfibrillated celluloses as reinforcement and a dispersant of CaCO3 in high-density polyethylene
31. Evaluation and Comparison of Daiokanzoto and Lubiprostone for Constipation: A Retrospective Cohort Study
32. A Survey of Health Food Use and Patient Satisfaction among Patients Undergoing Cancer Pharmacotherapy
33. Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all‐oral direct acting antivirals in patients with chronic hepatitis C virus infection
34. Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer
35. Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics
36. Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
37. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
38. Tolerability and safety of real‑world use of pomalidomide in patients with relapsed/refractory multiple myeloma
39. Effect of the timing of discontinuation of last‑line chemotherapy on patient prognosis in advanced and recurrent gastric cancer
40. Effectiveness of a Pharmacist Outpatient Service for Patients Receiving Monotherapy with Oral Anticancer Drugs through Management of Unused Prescribed Medicines
41. Evaluation of a Prospective Audit and Feedback Intervention by Pharmacists for Patients Receiving Intravenous Antibiotics
42. The incidence and timing of leukocyte overshoot after pegfilgrastim administration
43. Evaluation of treatment outcomes of patients with MRSA bacteremia following antimicrobial stewardship programs with pharmacist intervention
44. Three New 5,6-Dihydro-α-pyrones Isolated from Cryptocarya nitens
45. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database
46. Efficacy and Safety of Daikenchuto for Constipation and Dose-Dependent Differences in Clinical Effects
47. Dependence of the Electrochemical Redox Properties of Fullerenes on Ionic Liquids
48. Investigation on the Relationship between Initial Dose and Treatment Duration of Lenalidomide for Multiple Myeloma
49. Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer
50. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.